Apple Restores Telegram to App Store After Content Policy Violation 
Telegram Restored on Apple App Store After Temporary Removal 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
EDEN PRAIRIE, Minn., April 02, 2018 -- CHF Solutions (Nasdaq:CHFS), today announces that it will present at The MicroCap Conference on April 9, 2018.
The company’s CEO, John Erb, will present at 2:00 PM ET at The Essex House in New York City. The company will also be available for one-on-one investor meetings. Interested investors may request a meeting time by contacting Bret Shapiro, COREIR, either by calling 516-222-2560 or via [email protected].
About CHF Solutions
CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.
CONTACTS:
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
[email protected]
-or-
Bret Shapiro
Managing Partner
CORE IR
516-222-2560
[email protected]
www.coreir.com
MEDIA
Jules Abraham
JQA Partners, Inc.
917-885-7378
[email protected]
